Innovation in gene therapies is hard, but also potentially ground-breaking and biotechnology firm Medera is taking its decades-long journey in the space to the public markets just as hits its next steps in the clinical process.
This week, we speak with Medera CEO Ronald Li, and Kenneth Wong, CEO and Chairman of Keen Vision Acquisition Corp. The two announced a $622 million dollar combination in September.
Ron explains how Medera has leveraged years of innovations including the capacity to grow miniature human hearts for testing as it advances gene therapies for heart failure that do not rely on animal testing and could prove significantly cheaper than alternatives.
Kenneth tells us why he believes those details align well with the changing regulatory and investment climate around drug development. And, why he views Medera as being a more mature investment play in the biotech space than many of the others coming to market today.
Give it a listen.
Terms Tracker for the Week Ending December 20, 2024 Welcome to our weekly column where we discuss the findings from our IPO terms tracker based on the previous week’s pricings. * We will be skipping next week’s Terms Tracker post while we work on putting together our “2024 Year End Review”. You can find 2023’s...
Four Leaf Acquisition Corporation (NASDAQ:FORL) has entered into a definitive agreement to combine with Chinese technology firm Xiaoyu Dida for undisclosed terms. The Guangzhou, China-based firm produces software and hardware for smart car washing systems. The parties have set December 31, 2025 as the initial outside date and the combined company is expected to trade...
At the SPAC of Dawn SPACs are back on the board with a new deal announcement, which is the first in a little over two weeks. This brings the fourth quarter count on fresh deals to a still-meager nine after 27 were announced in the third quarter. By contrast, this quarter has still seen more...
Range Capital Acquisition Corp. (NASDAQ: RANGU) announced the pricing of its $100 million IPO and its units are expected to begin trading on the Nasdaq under the symbol “RANGU”, Friday, December 20, 2024. The new SPAC intends to take a generalist approach in searching for a business combination, but will seek opportunities in capital constrained...
SPAC Deja Vu There’s been a lot of talk this year in the SPAC market about how it’s finally reverting back to a healthier version of deal flow and the comparison is always, “….like 2019”. In fact, in 2019, Trump was in office and there were 59 SPAC IPOs priced. As of this morning, Trump...